---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-397037"
form_type: "8-K"
ticker: "MGX"
cik: "0001785279"
company_name: "Metagenomi Therapeutics, Inc."
filed_at: "2026-09-22T00:49:24+00:00"
generated_at: "2026-09-22T10:05:48.113359+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# Metagenomi furnishes Sep 2026 corporate presentation; deck details not in filing text

## Summary
- MGX issued a Sept 2026 corporate presentation positioning itself in precision gene editing for durable, curative medicines.
- Filing text ends after company tagline; specific pipeline, financials, or partnerships were not reproduced in this extract.
- Jian Irish, Ph.D., M.B.A. remains President and CEO per the 8-K signature block.
- Company is an emerging growth company; shares trade on Nasdaq under ticker MGX.

## SEC filing metadata
- accession: 0001193125-26-397037
- form_type: 8-K
- ticker: MGX
- cik: 0001785279
- company_name: Metagenomi Therapeutics, Inc.
- filed_at: 2026-09-22T00:49:24+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785279/000119312526397037/0001193125-26-397037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785279/000119312526397037/mgx-20260921.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-397037
- JSON: https://secwatch.observer/filing/0001193125-26-397037.json
- Plain text: https://secwatch.observer/filing/0001193125-26-397037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.